Microbes play important roles in human health and disease either as individual species or as a consortium. While medical microbiology has traditionally associated a single species with a specific disease, recent knowledge of the diversity of microbes present at different sites of the body has opened our eyes to the dynamic interactions between species, and how community interactions amongst microbes could potentiate disease. More importantly, clinical manifestations of disease symptoms have been hypothesized to arise from cross-interactions between metabolites and signalling molecules secreted by microbes not in direct communication with each other. Such myriad and entangled interactions raise important questions on clinicians and researchers' quest to understand the aetiologies of disease and underpinnings of their progression. Doing so require profiling the microbes present and their community structure, to which mass spectrometry metabolomics could lend a lens. Nevertheless, how do we associate specific diseases
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Microbes are present on all surfaces of the human body and forms an intricate but up-tonow poorly understood signalling and metabolic network with human cells. More importantly, many diverse species of bacteria, fungi, viruses and mycoplasmas cohabit human body surfaces with host cells, which is an interesting ecological system important in health and disease. Such collection of microbes at a specific locale is known as a microbiota, and they are differentiated in community structure and dynamics depending on the specific site in and on the human body that microbes reside.
The important concept pertinent to understanding microbiota's function lies in the collective phenotypic presentation of the assemblage of microbes, each playing different roles in the community, such as in metabolism, signalling, and cellular movement. Hence, microbiome function and capabilities are a meshwork of diverse interactions between different microbes which may be symbiont to a nearby species, but a keen nutrient competitor to a more distant microbe. Such entangled web of interactions at the nutrient, signalling and metabolism levels highlight a potential difficulty in understanding, in totality, the meaning and function of metabolic and signalling cross-talks between different species of the same microbiota. Coupled to host cellsmicrobe interaction, the amount of information and metabolite flows between the microbiota and host portends a significant bioinformatic challenge.
With growing understanding of microbiota's role in potentiating different stages of disease progression as well as other states of health, there is increasing research seeking to find microbial potentiators of disease within the microbiota closest in distance to the disease site. But what is the relevant question one should ask in associating a microbe or groups of microbes to a specific disease? Enter the concept of microbiome-wide association studies. In a review paper published in Nature, Rob Knight and coauthors ("Microbiome-wide association studies link dynamic microbial consortia to disease", Nature, Vol. 535, pp. 94-103, Link) 1 reviews recent research concerning the possibilities of linking different microbiota to specific diseases at the individual and population level. Specifically, the concept revolves around the association of metabolites pertinent to specific diseases to the microbes responsible for their secretion.
But, due to the presence of a large diversity of microbes in each microbiota, and the possibility of cross interaction between microbiota at different locales for engendering a specific disease, significant difficulty exists in pinpointing a causative link between a microbe to a specific disease, especially in multi-factorial diseases. Specifically, while it is technically possible to understand the aetiological agent of a disease (such as infectious disease) with respect to Koch's Principles, it remains difficult to identify the specific factors that may be responsible for potentiating each stage of a complex disease such as diabetes. In complex diseases such as metabolic syndrome, multiple metabolites secreted by microbes as well as the inflammation they caused, together with environmental factors associated with changeable lifestyle add to the plethora of links and connections requiring understanding, which makes the firm association of a specific set of factors to a syndrome difficult.
Looking at the broader scale of the problem, attempts at linking a specific microbiome to a disease is a mathematically under-determinate question, due to the myriad interactions between microbes that together result in genesis of disease. In essence, specific disease symptoms only arises due to the presence of a specific set of microbes that secrete metabolites or signalling molecule important to disease. More importantly, bioinformatic challenge aside, the larger question revolves around the utility of understanding, in broad terms, how one microbiome affects disease progression, where the focus should be on uncovering the specific molecular mechanisms resulting in disease.
From the disease treatment perspective, micro-scale understanding of the specific pathways and enzymes responsible for different pathologies at the clinical level give rise to leads suitable for the development of pharmaceutical agents that act, at the molecular level, in ameliorating clinical symptoms. Thus, what is the clinical value of understanding the association between microbiome and disease? Are we limited by the technology necessary to tease apart the complex web of microbes, signalling molecules and metabolites, that in aggregate, lead to observed phenotypic presentation of disease? Or, do we lack the bioinformatic capacity and capability to dissect entangled web of interactions of microbial species each performing different roles in the microbiome as they energize an environment suitable for their growth, but which may be detrimental for the host? Specifically, since a single metabolite could be secreted by multiple microbes, it would be hard to associate a metabolite to a specific microbe using omics discovery methods and bioinformatic approaches.
Collectively, understanding the microbiome responsible for specific diseases point us one step closer to determining the aetiological agent and processes underpinning disease manifestation and progression. While modern discovery science approaches centred on genome sequencing and mass spectrometry metabolomics opens up wide swathe of data space amenable for bioinformatic analysis, they nevertheless face daunting challenges in identifying critical links between specific microbes, metabolites, signalling factors or processes underlying diseases, particularly those of the multifactorial nature, such as the emerging global health threat of metabolic syndrome. Thus, what is the future trajectory of research seeking a correlation between microbiome and disease, in what is known as microbiome-wide association studies? The answer is the approach may not yield knowledge precise enough to answer basic clinical questions such as how changes in microbiome composition affect the severity of disease. But, profiling the microbiome composition at specific body sites do offer a glimpse into the dynamics of how microbes interact and shape human physiological processes, whose mysteries remain elusive as we probe deeper into host-microbe interactions.
